Taysha Gene Therapies (TSHA) Other Non-Current Assets (2019 - 2026)

Taysha Gene Therapies has reported Other Non-Current Assets for 6 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 6.31% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 6.31% YoY) and the FY2025 annual result came in at $2.3 million, down 10.96% from the prior year.
• Other Non-Current Assets improved to $2.8 million in Q1 2026 per TSHA's latest filing, from $2.3 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $2.8 million in Q1 2026 and troughed at $304000.0 in Q4 2023.
• A 5-year average of $2.4 million and a median of $2.6 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slumped 88.47% in 2023, then jumped 755.26% in 2024.
• Over 5 years, Other Non-Current Assets stood at $2.6 million in 2022, then plunged by 88.47% to $304000.0 in 2023, then surged by 755.26% to $2.6 million in 2024, then dropped by 10.96% to $2.3 million in 2025, then advanced by 19.4% to $2.8 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.8 million, $2.3 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.